Houston, Texas — Speratum Biopharma, Inc., a preclinical-stage oncology company developing RNAi-based therapeutics for aggressive, drug-resistant cancers, is excited to announce that it has joined Johnson & Johnson’s global incubator network, JLABS, as a resident of JLABS TMC. JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology sectors.

“Joining JLABS marks a major milestone for Speratum,” said Christian Marín Müller, Founder and CEO. “Our team is driving a bold RNAi platform that could reshape how we treat the toughest cancers. JLABS gives us the ecosystem to accelerate toward the clinic and create meaningful impact for patients, placing us in the heart of the Texas Medical Center ecosystem.”